DE102021000073A1 - Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological-hybrid therapeutic preventive drug for oral intake - Google Patents
Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological-hybrid therapeutic preventive drug for oral intake Download PDFInfo
- Publication number
- DE102021000073A1 DE102021000073A1 DE102021000073.0A DE102021000073A DE102021000073A1 DE 102021000073 A1 DE102021000073 A1 DE 102021000073A1 DE 102021000073 A DE102021000073 A DE 102021000073A DE 102021000073 A1 DE102021000073 A1 DE 102021000073A1
- Authority
- DE
- Germany
- Prior art keywords
- zinc
- combination preparation
- nystatin
- immunological
- active ingredient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 239000011701 zinc Substances 0.000 title claims abstract description 19
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 title claims abstract description 7
- 229940079593 drug Drugs 0.000 title claims abstract description 7
- 229960000988 nystatin Drugs 0.000 title claims abstract description 7
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 4
- 230000003449 preventive effect Effects 0.000 title claims abstract 3
- 239000004480 active ingredient Substances 0.000 title claims description 9
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims abstract description 6
- 210000000987 immune system Anatomy 0.000 claims description 12
- 230000004060 metabolic process Effects 0.000 claims description 11
- 230000000694 effects Effects 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000012678 infectious agent Substances 0.000 claims description 2
- 238000011866 long-term treatment Methods 0.000 claims description 2
- 230000003340 mental effect Effects 0.000 claims description 2
- 230000000813 microbial effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000004663 cell proliferation Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 6
- 241000233866 Fungi Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011885 synergistic combination Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940062776 zinc aspartate Drugs 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- BRKFIPNBXFDCDM-MDTVQASCSA-L zinc;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoate Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC1=CNC=N1.[O-]C(=O)[C@@H](N)CC1=CNC=N1 BRKFIPNBXFDCDM-MDTVQASCSA-L 0.000 description 1
- POEVDIARYKIEGF-CEOVSRFSSA-L zinc;(2s)-2-aminobutanedioate;hydron Chemical compound [Zn+2].[O-]C(=O)[C@@H](N)CC(O)=O.[O-]C(=O)[C@@H](N)CC(O)=O POEVDIARYKIEGF-CEOVSRFSSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Pharmazeutisch antimikrobielles Kombinationspräparat auf Zink und Nystatin Wirkstoffbasis als ein immunologisch-hybridwirkendes therapeutisch präventives Arzneimittel zur oralen Einnahme.Pharmaceutical antimicrobial combination preparation based on zinc and nystatin as an immunological-hybrid therapeutic preventive drug for oral administration.
Description
Die vorliegende Erfindung nutzt die hybride Wirkstoffwirkung der beiden antimikrobiellen Substanzen Zink & Nystatin, wodurch es zur Reduzierung von Mikroorganismen (Pilzen, Bakterien, Viren ~ in ihrem Spektrum) im Körper kommt. Desweiten führt sie zur Entlastung des Immunsystems sowie zur Regenerierung des Metabolismus und Organismus.The present invention uses the hybrid active ingredient effect of the two antimicrobial substances zinc & nystatin, which leads to a reduction in microorganisms (fungi, bacteria, viruses ~ in their spectrum) in the body. Furthermore, it relieves the immune system and regenerates the metabolism and organism.
Der Anmelder hat überraschend festgestellt, dass die antimikrobellen Wirkstoffe in Kombination eine hybride Wirkung regenerativ auf das Immunsystem, Metabolismus, Verdauung, die Körperzellen und Organismus haben.The applicant has surprisingly found that the antimicrobial active ingredients in combination have a hybrid regenerative effect on the immune system, metabolism, digestion, body cells and organism.
In Folge von mannigfaltigen Ursachen körperlichen Störungen (Infektionen, ernährungsbedingt, Krankheiten, Nebenwirkungen v. Medikament, Überzucker, Mikroorganismen, kontaminiertes Wasser, Alkohol, Schlafstörung, ......) können der menschliche Organismus und sein Immunsystem geschwächt werden, wodurch es u. a. zur erhöhten Population an Pilzen, Bakterien, Viren kommt.The human organism and its immune system can be weakened as a result of various causes of physical disorders (infections, diet-related, illnesses, side effects of medication, excess sugar, microorganisms, contaminated water, alcohol, sleep disorders, ......), which means, among other things, to the increased population of fungi, bacteria, viruses.
Der Anmelder hat überraschend festgestellt, dass das Kombinationspräparat sekundär in Darm wirkt und eine Pufferzone zum Immunorgan ∼Darm bildet.The applicant has surprisingly found that the combination preparation acts secondarily in the intestine and forms a buffer zone to the immune organ ∼ intestine.
Mit der Einnahme des Zinkanteils und der darauffolgenden substanziellen Säuren-Spaltung, wirkt das Zink antimikrobiell, antiseptisch und entzündungshemmend. Es trägt zudem zur erhöhten Aufnahme von Zink (Ionen) und den Nährstoffen über den Stoffwechsel bei.With the ingestion of the zinc portion and the subsequent substantial acid splitting, the zinc has an antimicrobial, antiseptic and anti-inflammatory effect. It also contributes to the increased absorption of zinc (ions) and nutrients through metabolism.
Nystatin als Wirkstoff ist ebenfalls antimikrobiell, insbesondere reduziert das Antimykotikum (selektiv) die Pilze (Candida albicans und Aspergillus fumigatus, ...), was sich ebenfalls positiv auf den Stoffwechsel und das Immunsystem nachhaltig auswirkt, weil es auch dadurch immunologische Ressourcen freisetzt.Nystatin as an active ingredient is also antimicrobial, in particular the antimycotic (selectively) reduces the fungi (Candida albicans and Aspergillus fumigatus, ...), which also has a lasting positive effect on the metabolism and the immune system, because it also releases immunological resources.
Fast alle organischen Zellen nutzen Zink-Ressourcen zum Wachstum und zur Vermehrung. Die Pilze entnehmen Nährstoff zum Wachstum, bestimmte Viren benutzen Bakterien als Wirt zur Vermehrung in menschlichen Organismus. Hierdurch mindern die Mikroben Ressourcen und erzeugen zudem toxische (immunschwächende) Ausscheidungen.Almost all organic cells use zinc resources for growth and reproduction. The fungi take nutrients to grow, certain viruses use bacteria as hosts to multiply in the human organism. As a result, the microbes reduce resources and also produce toxic (immune-weakening) excretions.
Der Anmelder hat überraschend festgestellt, dass aufgrund der sekundären Wirkung des Kombinationspräparats, es primär im menschlichen Organismus zu kontinuierlich körperlicher Regenerierung kommt. Sekundär wurde eine Pufferzone geschaffen, immunologische Ressourcen akkumulierend freigegeben und es kam zu Erhöhung des Zinks sowie Nährstoffanreicherung im Stoffwechselprozess.The applicant has surprisingly found that due to the secondary effect of the combination preparation, there is primarily continuous physical regeneration in the human organism. Secondarily, a buffer zone was created, accumulating immunological resources were released, and there was an increase in zinc and nutrient enrichment in the metabolic process.
Der höhere Zinkanteil wirkt dabei signifikant beim Zinkstoffwechsel. Über den Zinkstoffwechsel wird der Organismus überwiegend mit rechtsdrehenden L (+) Milchsäuren versorgt. Zink ist ein essenzielles Spurenelement der Organismus, insbesondre der Immunorgane, Immunzellen und Hämatopoese.The higher zinc content has a significant effect on zinc metabolism. The organism is mainly supplied with right-handed L (+) lactic acids via the zinc metabolism. Zinc is an essential trace element of the organism, especially of the immune organs, immune cells and hematopoiesis.
Das Kombinationspräparat wirkt mit den sekundär und primär geschaffen Voraussetzungen substanziell optimierend im Metabolismus und beim Zellenbildungsprozessen sowie bei den komplexen Zellen des Immunsystems. Die Blutzellen (Hämatopoese) und die Hautzellen (obere Hautschicht) benötigen zum Beispiel ca. 30 Tage zu ihrer vollständigen Erneuerung. Viele Blutkörperchen haben nur eine begrenzte Lebensdauer, Thrombozyten ca. 3-10 Tage.With the secondary and primary conditions created, the combination preparation has a substantially optimizing effect on the metabolism and cell formation processes as well as on the complex cells of the immune system. For example, the blood cells (hematopoiesis) and skin cells (upper skin layer) need about 30 days to fully regenerate. Many blood cells only have a limited life span, thrombocytes approx. 3-10 days.
Als eine neue Refresh-Langzeitbehandlung und der daraus in Folge eine Auffrischung unter optimalen Wachstumsbedingungen der körpereigenen Zellen, erfolgt eine kontinuierliche körperliche mentale Regenerierung des Organismus. Das Kombinationspräparat ist daher auch für Kur-/Reha-Anwendungen prädestiniert.As a new long-term refreshment treatment and the resulting refreshment under optimal growth conditions of the body's own cells, there is a continuous physical and mental regeneration of the organism. The combination preparation is therefore also predestined for spa/rehab applications.
Aufgabe der Erfindung ist es, ein mikrobielles Mittel zu schaffen, das eine synergistische Kombination von Einzelstoffen enthält, durch welche der Organismus nachhaltig eine Hybrid-Wirkung erfährt.The object of the invention is to create a microbial agent that contains a synergistic combination of individual substances through which the organism experiences a lasting hybrid effect.
Der menschliche Organismus beherbergt bis ~ 2 KG Körperanteil an Pilzen, Bakterien und Viren. Virenpartikel können zudem sehr lange sich im Organismus aufhalten, da sie über keinen Stoffwechsel verfügen, wie z.B. Bakterien. Man schätzt dabei bis zu 100 000 unterschiedliche Virenpartikelarten die inaktiv im menschlichen Körper schlummern.The human organism accommodates up to ~ 2 kg body part of fungi, bacteria and viruses. Virus particles can also remain in the organism for a very long time because they do not have a metabolism such as bacteria. It is estimated that up to 100,000 different types of virus particles are dormant in the human body.
Die Reaktion des Immunsystems auf neue Viren ist von der Immunantwort auf den eingedrungenen Erreger abhängig und explizit von dem aktuellen Gesundheitszustand.The reaction of the immune system to new viruses depends on the immune response to the invading pathogen and explicitly on the current state of health.
Zu berücksichtigen ist dabei, dass hier kontinuierlich derartige komplexe Prozesse gegen ganz unterschiedliche Infektionserreger im gesamten Körper stattfinden, wobei etwa 75 % der Immunzellen im Darmgewebe (Darmfläche ca. 350 m2) aktiv sind.It must be taken into account that such complex processes against very different infectious agents take place throughout the body, with around 75% of the immune cells in the intestinal tissue (intestinal area approx. 350 m 2 ) being active.
Die Globalisierung und der Bevölkerungswachstum führen zunehmend weltweit zu mehr Epidemien. Dieses vergegenwärtigt die Notwendigkeit für ein in sich intaktes, stabiles Immunsystem und neue Behandlungsansätze.Globalization and population growth are increasingly leading to more epidemics worldwide. This brings to mind the need for an intact, stable immune system and new treatment approaches.
Die äquivalenten gentechnische Impfstoffe gegen Viren wirken nur selektiv und zeitlich begrenzte. Sie sind mit sehr hohen Risiken verbunden, da sie irreversibel das Immunsystem negativ verändern könnten. Ofen, ungeprüft bleibt auch dabei der Reziproke Einfluss der verschiedensten Pilze, Bakterie, Viren, Tumorzellen etc. im Organismus, der durch die Impfung verifizierten Immunantwort. Das Kombinationspräparat kann hierbei therapeutisch sinnvoll unterstützen.The equivalent genetic engineering vaccines against viruses only work selectively and for a limited time. They are associated with very high risks, as they could irreversibly negatively alter the immune system. Of course, the reciprocal influence of the various fungi, bacteria, viruses, tumor cells etc. in the organism on the immune response verified by the vaccination remains unchecked. The combination preparation can provide therapeutic support here.
Im Vergleich zu anderen Arzneien, ist das Kombinationspräparat mit seinen Wirkstoffen Zink & Nystatin zuverlässig und stabile, zudem sind nur geringfügiger Nebenwirkungen bekannt.Compared to other drugs, the combination preparation with its active ingredients zinc & nystatin is reliable and stable, and only minor side effects are known.
Neben den wissenschaftlich bestätigen medizinischen Behandlungserfolge bei Pilzbefall, Bakterie- und Vireninfektion, fühlten sich Probaten zudem nach der Behandlung mit dem Kombinationspräpart auch körperlich und mental gestärkt und sichtlich äußerlich regeneriert.In addition to the scientifically confirmed medical treatment successes for fungal, bacterial and viral infections, the test subjects also felt physically and mentally strengthened and visibly externally regenerated after treatment with the combination preparation.
Erfindungsgemäß kennzeichnet das Kombinationspräparat die vielseitigen medizinischen Anwendungen und die pharmazeutische Verwendung.According to the invention, the combination preparation characterizes the versatile medical applications and the pharmaceutical use.
Das Kombinationspräparat kann bei akuter Infektion durch Bakterien, Pilz oder Viren angewandte werden. Arzneimittel zur akkumulierenden Stärkung des Immunsystems. Als prophylaktisches Mittel vor oder nach einer Operation und anderen organischen Behandlungen als qualitätssichernde Maßnahme. Unterstützend in der Inkubationszeit gentechnischen Impfungen. Zur Refresh-Behandlung oder als Kur bzw. Reha begleitende Langzeitbehandlung, insbesondere zur körperlichen Regenerierung des Organismus.The combination preparation can be used in acute bacterial, fungal or viral infections. Drugs for accumulating strengthening of the immune system. As a prophylactic before or after surgery and other organic treatments as a quality assurance measure. Supportive in the incubation period of genetically engineered vaccinations. For refreshment treatment or as a cure or rehabilitation accompanying long-term treatment, especially for physical regeneration of the organism.
Der Wirkstoff Zink kann in üblichen pharmazeutischen, annehmbaren Formen vorliegen wie Zinkhistidinat, Zinkoronat, Zinkgluconat oder Zinkaspartat.The active ingredient zinc may be in conventional pharmaceutically acceptable forms such as zinc histidinate, zinc coronate, zinc gluconate or zinc aspartate.
Nährstoffbezugswert Zink 10mg/Tag EU-Verordnung 1169/2011 oder nach ärztlicher Verordnung.Nutrient reference value zinc 10mg/day EU regulation 1169/2011 or according to medical prescription.
Wirkstoff, Nystatin 500 000 I.E. (Internationale Einheit) oder WHO 4855 I.E. /mg oder nach ärztlicher Verordnung.Active substance, Nystatin 500,000 IU (International Unit) or WHO 4855 IU/mg or as prescribed by a doctor.
Das erfindungsgemäße Kombinationspräparat kann gegebenenfalls noch weite Wirkstoffe enthalten, z.B. Vitamine, Kalzium oder Magnesium. Notwendige Hilfsstoffe entsprechend der Darreichungsform.The combination preparation according to the invention can optionally also contain other active ingredients, e.g. vitamins, calcium or magnesium. Necessary excipients according to the dosage form.
Detaillierter Gebrauchsinformationen werden in der Zugelassenen Arznei wiedergegeben.Detailed instructions for use are reproduced in the Approved Drug.
Sollte sich der wiedergegebene Behandlungserfolg nicht einstellen, so können möglicherweise organische Probleme oder auch hohe toxische Wert im Serum des Organismus vorliegen, die insbesondere dann auf das Immunsystem wirken.If the reported treatment success does not occur, there may be organic problems or high toxic values in the serum of the organism, which then have an effect on the immune system in particular.
Elementar vorausgesetzt werden auch eine ausgewogene Ernährung und die Deckung des Flüssigkeitsbedarfs entsprechend der offiziellen Empfehlungen.Eating a balanced diet and covering your fluid needs in accordance with the official recommendations are also essential.
Ein möglicher Anhaltspunkt für ein starkes Immunsystem sind die Augen mit ihren Zinkstoffwechsel, die auch als Zinkspeicher gelten (morgens klar und weiß, bläulich schirmend).A possible indication of a strong immune system are the eyes with their zinc metabolism, which are also considered zinc stores (clear and white in the morning, bluish shielding).
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102021000073.0A DE102021000073A1 (en) | 2021-01-07 | 2021-01-07 | Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological-hybrid therapeutic preventive drug for oral intake |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102021000073.0A DE102021000073A1 (en) | 2021-01-07 | 2021-01-07 | Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological-hybrid therapeutic preventive drug for oral intake |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE102021000073A1 true DE102021000073A1 (en) | 2022-07-07 |
Family
ID=82020748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE102021000073.0A Pending DE102021000073A1 (en) | 2021-01-07 | 2021-01-07 | Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological-hybrid therapeutic preventive drug for oral intake |
Country Status (1)
| Country | Link |
|---|---|
| DE (1) | DE102021000073A1 (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120329742A1 (en) | 2006-02-01 | 2012-12-27 | Weg Stuart L | Use of antifungal compositions to treat upper gastrointestinal conditions |
-
2021
- 2021-01-07 DE DE102021000073.0A patent/DE102021000073A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120329742A1 (en) | 2006-02-01 | 2012-12-27 | Weg Stuart L | Use of antifungal compositions to treat upper gastrointestinal conditions |
Non-Patent Citations (1)
| Title |
|---|
| CN 103 638 039 B (WPI-Zusammenfassung und Computer-Übersetzung) |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE502007010071C5 (en) | USE OF A MINERAL COMPOSITION AND, WHERE APPROPRIATE, ACETOGENIC AND / OR BUTYROGENIC BACTERIA TO AVOID OR REDUCE GAS FORMATION IN THE THICKNESS OF ANIMALS AND THEREFORE COMPLAINED ABDOMINAL | |
| US10195239B2 (en) | Extract of Trigonella foenum-graecum | |
| DE69100314T2 (en) | Treatment of Clostridium difficile diarrhea and pseudomembrane colitis. | |
| TW200824700A (en) | Dermal drops | |
| Sindhusha et al. | Formulation of Neem and Echinacea gel for oral health along with the evaluation of antimicrobial, cytotoxic, anti-inflammatory, and free radical scavenging activity: An in vitro study | |
| EP3592390B1 (en) | Agent for use in the treatment of dyslipidemia | |
| DE60124516T2 (en) | COMBINATION OF THE LEZITHINE WITH ASCORBIC ACID | |
| DE102021000073A1 (en) | Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological-hybrid therapeutic preventive drug for oral intake | |
| DE202020004830U1 (en) | Pharmaceutical antimicrobial combination preparation based on zinc - nystatin - active ingredient as an immunological hybrid acting therapeutic preventive drug for oral use | |
| US10149831B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| EP1565197B1 (en) | Use of papaya puree for the treatment of digestive troubles | |
| DE202007008818U1 (en) | Composition for the treatment of infections | |
| DE19633446B4 (en) | Medicinal products with lipid-lowering action | |
| Martin et al. | The effects of a novel red spinach extract on graded exercise testing performance | |
| JP2007501856A (en) | Migraine medication | |
| CN106539817A (en) | For treating ointment, the preparation method and its usage of acne | |
| US10166265B1 (en) | Pharmaceutical composition for treating bacterial and viral infections | |
| DE112012001272T5 (en) | Composition of substances affecting the microbial flora and tissue in the human intestine "Protobiol". Manufacturing process and application | |
| CN106581660A (en) | Composition for treating microbial infection | |
| AU2008241370B2 (en) | Essential oil of kunzea ambigua and methods of use | |
| EP4180047A1 (en) | Method for carrying out a fasting course for seriously ill patients | |
| DE102020006049A1 (en) | deoxycholic acid and its compounds for use in the treatment of diseases | |
| EP4680225A1 (en) | Pharmaceutical composition comprising cannabidiol and bacillus subtilus | |
| DE202005007462U1 (en) | Medicament or nutritional supplement composition, for combating chronic viral infections, containing vitamin C, vitamin E, coenzyme Q10, carotenoids, selenium, zinc and copper | |
| CN102228493B (en) | Medicine for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R012 | Request for examination validly filed | ||
| R016 | Response to examination communication | ||
| R016 | Response to examination communication |